In phase 1, 75% of patients had also received chemotherapy whereas only 31% had in phase 2. In the phase 1 portion of the trial, ARV-110 doses ranged from 35–700 mg QD or 210–420 mg BID. Based on ...

Key Takeaways ART-101, a novel PSMA-targeting small molecule, received FDA IND clearance for mCRPC treatment, enabling a phase 1 trial launch. Preclinical studies show ART-101 has higher tumor uptake ...

The Maharashtra Cabinet on Tuesday gave approval to develop the first phase of the ambitious Virar-Alibaug Multi-Modal Transport Corridor, a 165-km arterial route designed to reduce congestion in ...

Eyestem has announced the completion of its phase 1 study for its investigational retinal pigment epithelium (RPE) cell therapy, Eyecyte-RPE. The company has submitted the results to the Central Drugs ...

Thin films of isotactic polybutene-1 (iPBu) with large lathlike flat-on form II crystals were prepared by isothermal crystallization from melt at 105 °C. The II–I phase transition of this kind of thin ...

Infusion-related reactions (grade 1–2) were seen in 6 mg/kg (40.0%) and 10 mg/kg (66.7%) regimens: In the efficacy-evaluable population, confirmed PSA50 (a key secondary endpoint for phase 2) was ...

In this article, a single-phase transformerless inverter for photovoltaic (PV) applications is introduced. The proposed inverter provides common ground between input and output terminals, which ...

This letter proposes a phase-locked loop (PLL) able to operate as an independent single-phase PLL in the context of three-phase systems. Its key advantage is that the extracted information allows the ...

The 8.4% weight loss mark reported Monday was achieved by the 1.2 mg dose, the highest of four doses of the drug administered weekly for five weeks in a two-part Phase 1 study. Each part enrolled ...

Placebo-subtracted mean weight loss up to 8.4% at Day 36 19-day observed half-life supports once-monthly dosing as monotherapy and potential first-in-category monthly GLP-1 + Amylin combination ...

Innovent Biologics presents data from phase 1 PoC study of IBI363 to treat advanced NSCLC at 2025 ASCO San Francisco Friday, June 6, 2025, 18:00 Hrs [IST] Innovent Biologics, Inc. (Innovent), a ...